See more : Omnicom Group Inc. (OMC) Income Statement Analysis – Financial Results
Complete financial analysis of Kamada Ltd. (KMDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kamada Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Multi Ways Holdings Limited (MWG) Income Statement Analysis – Financial Results
- Prism Johnson Limited (PRSMJOHNSN.NS) Income Statement Analysis – Financial Results
- BASF SE (BAS.SW) Income Statement Analysis – Financial Results
- Aurora Technology Acquisition Corp. (ATAKU) Income Statement Analysis – Financial Results
- Xinjiang Guannong Fruit & Antler Co.,Ltd. (600251.SS) Income Statement Analysis – Financial Results
Kamada Ltd. (KMDA)
About Kamada Ltd.
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 142.52M | 129.34M | 103.64M | 133.25M | 127.19M | 114.47M | 102.83M | 77.49M | 70.11M | 71.93M | 70.62M | 72.68M | 55.92M | 36.27M | 14.98M | 15.21M | 13.44M |
| Cost of Revenue | 87.03M | 82.64M | 73.31M | 85.69M | 77.45M | 73.00M | 70.74M | 55.84M | 54.11M | 56.31M | 44.22M | 49.98M | 40.20M | 30.20M | 15.83M | 15.14M | 10.28M |
| Gross Profit | 55.49M | 46.70M | 30.33M | 47.55M | 49.74M | 41.47M | 32.09M | 21.65M | 16.01M | 15.62M | 26.41M | 22.69M | 15.72M | 6.07M | -847.15K | 70.83K | 3.16M |
| Gross Profit Ratio | 38.94% | 36.11% | 29.26% | 35.69% | 39.11% | 36.23% | 31.21% | 27.94% | 22.83% | 21.72% | 37.39% | 31.23% | 28.11% | 16.74% | -5.66% | 0.47% | 23.52% |
| Research & Development | 13.93M | 13.17M | 11.36M | 13.61M | 13.06M | 9.75M | 11.97M | 16.25M | 16.53M | 16.03M | 12.75M | 11.82M | 11.03M | 9.76M | 0.00 | 12.37M | 0.00 |
| General & Administrative | 18.25M | 12.80M | 12.64M | 10.14M | 9.19M | 8.53M | 8.27M | 7.64M | 7.04M | 7.59M | 7.86M | 4.41M | 4.82M | 4.78M | 13.83M | 4.11M | 16.63M |
| Selling & Marketing | 9.20M | 15.28M | 6.28M | 4.52M | 4.37M | 3.63M | 4.40M | 3.24M | 3.86M | 2.90M | 2.10M | 1.85M | 2.19M | 2.26M | 236.80K | 631.68K | 196.59K |
| SG&A | 27.45M | 28.09M | 18.91M | 14.66M | 13.56M | 12.16M | 12.67M | 10.89M | 10.90M | 10.49M | 9.96M | 6.26M | 7.01M | 7.04M | 14.07M | 4.74M | 16.83M |
| Other Expenses | 4.04M | 912.00K | 753.00K | 49.00K | 330.00K | 997.00K | 649.00K | 712.00K | 524.00K | 455.00K | 444.00K | 373.00K | 0.00 | 0.00 | 749.21K | 0.00 | 1.10M |
| Operating Expenses | 45.43M | 42.17M | 31.02M | 28.32M | 26.95M | 22.21M | 24.64M | 27.13M | 27.43M | 26.52M | 22.71M | 18.46M | 18.04M | 16.81M | 14.82M | 17.11M | 17.93M |
| Cost & Expenses | 132.46M | 124.81M | 104.34M | 114.01M | 104.40M | 95.21M | 95.38M | 82.98M | 81.54M | 82.83M | 66.92M | 68.44M | 58.24M | 47.01M | 30.65M | 32.26M | 28.21M |
| Interest Income | 588.00K | 91.00K | 295.00K | 1.03M | 1.15M | 820.00K | 500.00K | 469.00K | 463.00K | 1.61M | 289.00K | 578.00K | 2.62M | 589.63K | 116.42K | 85.25K | 216.82K |
| Interest Expense | 1.30M | 914.00K | 1.28M | 266.00K | 293.00K | 340.00K | 162.00K | 126.00K | 934.00K | 3.09M | 3.15M | 3.36M | 3.79M | 5.03M | 4.04M | 4.60M | 442.71K |
| Depreciation & Amortization | 11.47M | 11.61M | 5.83M | 5.25M | 4.66M | 3.56M | 3.65M | 3.36M | 3.23M | 2.79M | 3.00M | 3.04M | 2.86M | 2.78M | 2.47M | 2.37M | 2.13M |
| EBITDA | 21.53M | 4.53M | 5.20M | 25.41M | 27.30M | 23.46M | 11.25M | -1.98M | -7.10M | -8.31M | 8.09M | 7.18M | 2.72M | -9.38M | -15.52M | -14.67M | -20.33M |
| EBITDA Ratio | 15.11% | 8.13% | 5.02% | 18.88% | 22.37% | 20.78% | 11.15% | -1.95% | -11.03% | -9.04% | 9.90% | 10.81% | 5.64% | -21.93% | -87.98% | -96.45% | -93.31% |
| Operating Income | 10.06M | -1.64M | -401.00K | 19.24M | 22.78M | 19.26M | 7.44M | -5.84M | -11.42M | -10.90M | 3.70M | 4.24M | -2.32M | -10.73M | -16.37M | -17.04M | -16.32M |
| Operating Income Ratio | 7.06% | -1.27% | -0.39% | 14.44% | 17.91% | 16.82% | 7.24% | -7.54% | -16.29% | -15.16% | 5.24% | 5.83% | -4.14% | -29.59% | -109.31% | -112.02% | -121.42% |
| Total Other Income/Expenses | -1.64M | -6.79M | -1.19M | -672.00K | 197.00K | 1.08M | -274.00K | 470.00K | 154.00K | -1.68M | -3.23M | -3.46M | -1.18M | -4.44M | -5.66M | 4.60M | -6.58M |
| Income Before Tax | 8.43M | -2.26M | -1.89M | 18.57M | 22.98M | 20.34M | 7.17M | -5.01M | -11.27M | -12.58M | 467.00K | 783.00K | -3.49M | -15.17M | -22.03M | -12.45M | -22.90M |
| Income Before Tax Ratio | 5.91% | -1.75% | -1.82% | 13.93% | 18.07% | 17.77% | 6.97% | -6.47% | -16.07% | -17.49% | 0.66% | 1.08% | -6.25% | -41.83% | -147.09% | -81.81% | -170.39% |
| Income Tax Expense | 145.00K | 62.00K | 345.00K | 1.43M | 730.00K | -1.96M | 269.00K | 1.72M | -154.00K | 52.00K | 24.00K | 523.00K | 3.79M | 4.44M | 5.66M | -4.60M | 8.13M |
| Net Income | 8.28M | -2.32M | -2.23M | 17.14M | 22.25M | 22.30M | 6.90M | -6.73M | -11.27M | -12.64M | 443.00K | 260.00K | -3.49M | -15.17M | -22.03M | -12.45M | -22.90M |
| Net Income Ratio | 5.81% | -1.79% | -2.15% | 12.86% | 17.49% | 19.48% | 6.71% | -8.69% | -16.07% | -17.57% | 0.63% | 0.36% | -6.25% | -41.83% | -147.09% | -81.81% | -170.39% |
| EPS | 0.17 | -0.05 | -0.05 | 0.42 | 0.57 | 0.55 | 0.18 | -0.18 | -0.31 | -0.35 | 0.01 | 0.01 | -0.13 | -0.61 | -0.88 | -0.94 | -2.16 |
| EPS Diluted | 0.15 | -0.05 | -0.05 | 0.41 | 0.57 | 0.55 | 0.18 | -0.18 | -0.31 | -0.35 | 0.01 | 0.01 | -0.13 | -0.61 | -0.88 | -0.94 | -2.16 |
| Weighted Avg Shares Out | 48.83M | 44.82M | 44.77M | 44.14M | 40.32M | 40.28M | 37.97M | 36.42M | 36.25M | 35.71M | 32.71M | 28.08M | 27.55M | 25.06M | 25.06M | 13.20M | 10.61M |
| Weighted Avg Shares Out (Dil) | 53.68M | 44.82M | 44.77M | 44.59M | 40.58M | 40.54M | 38.05M | 36.43M | 36.25M | 35.97M | 33.39M | 28.69M | 27.70M | 25.06M | 25.06M | 13.20M | 10.61M |
Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds
Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland
Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company's Facility in Israel
Kamada Ltd. (KMDA) Q4 2022 Earnings Call Transcript
Kamada Issues 2023 CEO Letter to Shareholders
Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company's Facility in Israel
Kamada Announces Planned Transition of Chief Financial Officer
New Strong Buy Stocks for November 28th
Source: https://incomestatements.info
Category: Stock Reports